In Vivo Kinematics for Subjects With Smith & Nephew Journey II BCS TKA, Journey II CR TKA, Or Journey II XR TKA
Multi-center In Vivo Kinematics for Subjects Implanted With Smith & Nephew Journey II BCS TKA, Journey II CR TKA, Or Journey II XR TKA
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37996
- The University of Tennessee
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients in the age range of 18 years to 85 years (both inclusive)
- Patients who have a BMI less than 35
- Patients who do not have previous surgery on the implanted knee that might restrict their movement
- Patient who are at least 6 months post-operative
- Patients who do not experience any pain or other post-operative complications
- Patients who have a stable TKA and can perform a deep knee bend activity
- Patients who are willing to participate in this study and are willing to sign appropriate HIPAA and informed consent forms
- Subjects will have a Journey II, either the BCS or XR, knee system
Exclusion Criteria:
- Pregnant, potentially pregnant, or lactating females. To satisfy radiation protocol, each female subject will be asked if she is pregnant, or possibly could be pregnant. A pregnant person will not be allowed to participate in the study.
- Patients who have currently enrolled in a fluoroscopic study within the past year.
- Patients currently involved in any personal injury litigation, medical/legal or workman's compensation claims.
- Patients with known drug or alcohol abuse histories or psychological disorders that could affect ability to complete all aspects of the study.
- Patients with neurological or musculoskeletal disorders that might adversely affect weight-bearing motion ability
- Subjects who are unable to perform a deep knee bend.
- Subjects who are unwilling to sign Informed Consent/ HIPAA documents.
- Subjects without the required type of knee implant.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Journey II Bi-Cruciate Stabilized
Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL resected
|
Total Knee Arthroplasty System
|
|
Journey II Cruciate Retaining
Subjects who have received a Journey II Total Knee Arthroplasty with only the ACL resected (therefore PCL retained)
|
Total Knee Arthroplasty System
|
|
Journey II Bi-Cruciate Retaining
Subjects who have received a Journey II Total Knee Arthroplasty with both the ACL and PCL retained
|
Total Knee Arthroplasty System
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medial AP Translations, in mm
Time Frame: At least 6 months postoperative
|
Anterior Posterior (AP) translations, in mm, of medial femoral condyle during Deep Knee Bend Activity.
Values are based on the participants range of motion throughout their DKB activity.
A positive number indicated anterior sliding from full extension to maximum flexion, and a negative number indicated posterior rollback from full extension to maximum flexion.
|
At least 6 months postoperative
|
|
Lateral AP Translations, in mm
Time Frame: At least 6 months postoperative
|
Anterior Posterior (AP) translations, in mm, of lateral femoral condyle during Deep Knee Bend Activity.
Values are based on the participants range of motion throughout their DKB activity.
A positive number indicated anterior sliding from full extension to maximum flexion, and a negative number indicated posterior rollback from full extension to maximum flexion.
|
At least 6 months postoperative
|
|
Maximum Flexion, in Degrees
Time Frame: At least 6 months postoperative
|
Maximum weight-bearing flexion, in degrees, during Deep Knee Bend Activity.
Maximum flexion indicated how far a participant can bend their knee during a DKB.
A larger number indicates greater flexion, i.e. more bending.
|
At least 6 months postoperative
|
|
Axial Rotation, in Degrees
Time Frame: At least 6 months postoperative
|
Axial Rotation, in degrees, during Deep Knee Bend Activity.
Values are based on the participants range of motion throughout their squat activity.
A positive number indicates external femorotibial axial rotation from full extension to maximum flexion, and a negative number indicates internal femorotibial axial rotation from full extension to maximum flexion.
|
At least 6 months postoperative
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Michael LaCour, PhD, The University of Tennessee
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WIRB20203268
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.